Unknown

Dataset Information

0

Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.


ABSTRACT: The major dilemma of cancer chemotherapy has always been a double-edged sword, producing resistance in tumor cells and life-threatening destruction of nontumorigenic tissue. Glioblastoma is the most common form of primary brain tumor, with median survival at 14 months after surgery, radiation and temozolomide (monofunctional alkylator) therapy. Treatment failure is most often due to temozolomide-resistant tumor growth. The underlying basis for development of tumor cell resistance to temozolomide instead of death is not understood. Our current results demonstrate that both cervical carcinoma (HeLa MR) and glioblastoma (U251) tumor cells exposed to an equivalent chemotherapeutic concentration of a monofunctional alkylator undergo multiple cell cycles, maintenance of metabolic activity, and a prolonged time to death that involves accumulation of Apoptosis Inducing Factor (AIF) within the nucleus. A minority of the tumor cell population undergoes senescence, with minimal caspase cleavage. Surviving tumor cells are comprised of a very small subpopulation of individual cells that eventually resume proliferation, out of which resistant cells emerge. In contrast, normal human cells (MCF12A) exposed to a monofunctional alkylator undergo an immediate decrease in metabolic activity and subsequent senescence. A minority of the normal cell population undergoes cell death by the caspase cleavage pathway. All cytotoxic events occur within the first cell cycle in nontumorigenic cells. In summation, we have demonstrated that two different highly malignant tumor cell lines slowly undergo very altered cellular and temporal responses to chemotherapeutic monofunctional alkylation, as compared to rapid responses of normal cells. In the clinic, this produces resistance and growth of tumor cells, cytotoxicity of normal cells, and death of the patient.

SUBMITTER: Gupte M 

PROVIDER: S-EPMC3760805 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator.

Gupte Maithili M   Tuck Andrew N AN   Sharma Vishal P VP   Williams Kandace J KJ  

PloS one 20130903 9


The major dilemma of cancer chemotherapy has always been a double-edged sword, producing resistance in tumor cells and life-threatening destruction of nontumorigenic tissue. Glioblastoma is the most common form of primary brain tumor, with median survival at 14 months after surgery, radiation and temozolomide (monofunctional alkylator) therapy. Treatment failure is most often due to temozolomide-resistant tumor growth. The underlying basis for development of tumor cell resistance to temozolomide  ...[more]

Similar Datasets

| S-EPMC1802559 | biostudies-literature
| S-EPMC1635729 | biostudies-literature
| S-EPMC8440934 | biostudies-literature
2009-10-01 | GSE10937 | GEO
| S-EPMC23897 | biostudies-literature
| S-EPMC6495872 | biostudies-literature
| S-EPMC10419530 | biostudies-literature
| S-EPMC3082844 | biostudies-literature
| S-EPMC3416046 | biostudies-literature
| S-EPMC10559169 | biostudies-literature